News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process


6/27/2013 10:40:15 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria. Genervon has received many inquiries from ALS patients interested to participate in the FDA approved IND GM604 clinical trial for ALS (clinicaltrials.gov NCT01854294). GM604’s mechanisms of action against ALS involve 12 pathways and up to 22 biological processes. It modulates over 80 specific ALS related genes interactively, systemically and dynamically. In order to stimulate the diseased and compromised axonal transport system and delay ALS onset and death of neurons, GM604 regulates 25 genes in this pathway alone. Further scientific details and informative videos can be found at www.genervon.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES